Combining HIV therapies; listing warning; $250 million acquisition.
Bristol-Myers Squibb Co., in Princeton, and Gilead Sciences Inc., in Foster City, Calif., announced Wednesday a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing a Bristol with Gilead’s boosting agent, effectively increasing blood levels of certain HIV medicines to potentially allow for once-daily dosing.
Senesco Technologies Inc., in New Brunswick, received notice Wednesday from the NYSE Amex LLC that the company does not meet one of its continued listing standards, as it had less than $6 million in stockholders’ equity June 30.
C.R. Bard Inc., in the Murray Hill section of New Providence, announced Tuesday it has reached a definitive agreement to acquire Medivance Inc., of Louisville, Colo., for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions.